Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

CATALYST investigators

科研成果: 期刊稿件 › 文章 › 同行评审

41 引用 （Scopus）

指纹

探究 'Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial' 的科研主题。它们共同构成独一无二的指纹。

Keyphrases

Medicine and Dentistry